China News Service, December 14th (Reporter Chen Jing) "Caught a tumor but died of the heart"?
This is not a joke.
Professor Ge Junbo, a member of the Chinese Academy of Sciences and Zhongshan Hospital affiliated to Fudan University, emphasized on the 14th that for patients with cancer and heart disease, one should not focus on just one disease.
On the same day, the reporter learned that Shanghai medical experts have successfully developed small programs to help doctors and cancer patients pay attention to the toxicity of therapeutic drugs to the heart.
Cheng Leilei introduced that it is necessary to develop, promote and use simple and convenient risk assessment methods for early screening of patients.
Photo courtesy of Zhongshan Hospital
It is reported that the cells of the human heart are constant. Once the cardiomyocytes die, because there is no reserve and compensation, they will often develop into a dangerous and critical illness.
Cardiovascular toxicity caused by various tumor treatment drugs and radiation rays requires special attention.
Ge Junbo told reporters that tumors and cardiovascular diseases are inseparable.
With the continuous development of treatment methods, many cancer patients can survive for a long time, and cancer has gradually become a "chronic disease."
For these patients, the quality of life for long-term survival must be improved. While cancer patients and their families pay attention to cancer treatment, they must not ignore heart monitoring!
On the same day, the team of Academician Ge Junbo was a guest at the "Science and Technology Living Room" to share the development and implementation of innovative achievements in clinical practice of tumor and heart disease, and the auxiliary application of new media platform tools.
Professor Xia Yunlong, head of the Oncology Cardiology Group of the Cardiovascular Branch of the Chinese Medical Association, and Professor Zhang Zhiren, chairman of the Integrated Oncology and Cardiology Branch of the Chinese Anti-Cancer Association, delivered speeches via video.
During the interview, the reporter learned that with the increase in the early detection rate of breast cancer and the continuous improvement of treatment methods, the number of breast cancer patients is increasing; at the same time, the survival period is prolonged, and the risk of long-term cardiac complications of cancer survivors also increases. The increase.
Ge Junbo told reporters that for middle-aged and elderly women, cardiovascular disease poses a greater threat of death than breast cancer itself.
On the day of the event, the "Breast Cancer Cardiotoxicity Online Evaluation Mini Program" and the "Immune Checkpoint Inhibitor Cardiotoxicity Online Evaluation Mini Program" developed by researchers from Zhongshan Hospital affiliated to Fudan University were launched.
Ge Junbo introduced that with the help of a small program, oncologists and patients can initially determine the risk of the heart by scanning the QR code.
Hospitals and companies jointly develop relevant test kits to benefit more cancer patients.
Photo courtesy of Zhongshan Hospital
Aunt Wang, a 52-year-old breast cancer patient, told reporters that while she is undergoing chemotherapy, she sometimes feels heartbeats.
Do chemotherapy drugs affect the heart and can treatment be continued?
Doctors use the "Breast Cancer Cardiotoxicity Online Assessment" small program to determine the risk level of the group as low-risk.
Aunt Wang said happily that it is very convenient to know if there is a risk by tapping a small mobile phone program!
"In fact, oncologists have relatively insufficient understanding of the cardiovascular risk of breast cancer patients, and it is easy to overlook the early clinical manifestations." Chief physician Cheng Leilei of the Department of Cardiac Ultrasound Diagnosis of Zhongshan Hospital introduced to reporters that the development and promotion of simple and convenient risks Evaluation methods are necessary for early screening of patients.
During the interview, the reporter learned that at present, immune checkpoint inhibitors that use autoimmune cells to kill tumors have become new anti-cancer drugs, giving cancer patients the light.
Ge Junbo believes that the widespread use of such drugs will become an inevitable trend.
But the immune toxicity of various organs has also become a new problem.
Immune checkpoint inhibitor-related myocarditis has the highest mortality rate, and early identification and treatment have become a common challenge for oncologists and cardiovascular physicians.
Another "Cardiotoxicity Online Assessment Mini Program" launched on the same day provides an assessment method for the cardiotoxicity of immune checkpoint inhibitors, which can help non-cardiovascular physicians assess the risk of cardiovascular events in cancer patients, and quickly identify high risks at an early stage People, seek professional treatment as soon as possible.
According to reports, the oncology and cardiology team of Zhongshan Hospital affiliated to Fudan University has discovered myocardial damage markers that can predict the outcome of immune myocarditis.
The hospital has joined hands with relevant companies to develop relevant test kits to benefit more cancer patients.
(Finish)